Anheuser-Busch InBev SA/NV BUD

Key data

The business

AB InBev is the world's largest brewer: about one in four beers sold on earth carries one of its roughly 500 labels. The money is made two ways. First, a portfolio of premium brands, Corona, Michelob Ultra, Stella Artois, that people pay up for, which lifts the price per case even when the case count is flat. Second, sheer dominance in emerging markets, especially Brazil, Colombia, Mexico and South Africa, where it is the default beer and owns the distribution trucks, the coolers, and the corner-store relationships. That scale is the moat: a new brewer can copy a recipe but not thirty thousand routes. The scar in the portfolio is US Bud Light, whose volumes never fully recovered from the 2023 boycott, which is why the American business is a smaller slice of the story than it was five years ago.

The numbers

Revenue in dollars has gone nowhere for four years, and that is the first thing to understand about this name.

The top line grew 6.9% in the latest half, but the $6.3B bottom line is flattered by non-operating gains and should not be read as a doubling of the real business; the underlying half was in line with the steady grind above it. The truer meter is the annual record.

Flat revenue hides currency: reported dollars are dragged down by weak Latin American money, while volumes run flat to slightly lower and price and premium mix carry the rest. What compounds sits below the top line and in the cash.

Free cash per share went from $3.79 in 2022 to $5.68 in 2025, a 14.4% annual climb, while diluted EPS grew 5.9% and shares shrank 3.2%. On a flat top line, that is the whole machine: steady operating profit, less interest as debt falls, and a share count that finally moves. What I believe the market underweights is the debt lever itself, net debt is down to 2.3 times cash earnings from north of four, and the print that settles it is how large the next buyback authorization runs.

Management

Doukeris's team is doing the unglamorous work well. The 2025 repurchase more than doubled to $2.3B at an average price near $61.78, and with the stock at $80 that capital was spent well below today's quote, the mark of a buyer who waited. Dividends nearly doubled year over year, and the deleveraging that pays for both is the single clearest achievement of this stretch. Since this summer the H1 2026 report kept that read intact: cash generation and the buyback pace both held rather than faded. There was no open-market insider buying or selling in the last twelve months, so the signal is in the capital allocation, not the Form 4s. Pay detail was not disclosed in this run.

How it fails or surprises you

Volume finally outruns price. The top line holds on price and premium mix while cases sold drift lower. If organic volume decline steepens past roughly 2% over the next two halves and pricing can no longer cover it, reported revenue turns negative and the flat-line story becomes a shrinking one. Watch the volume-versus-price split in the next release; volume is the truth, ticket can be inflation.

The debt lever keeps unlocking cash (right tail). At 2.3x net leverage, each turn paid down converts directly into buyback capacity the market is not paying for at a 9.8% free-cash yield. If the 2026 authorization scales past $3B to $4B, per-share compounding accelerates from mid-single digits toward double, and the multiple can re-rate off "melting staple." The print that reveals it first is the buyback size set with full-year results.

The earnings base is not what it looks like. The strongest fact against this memo is that H1 2026 net income doubled on items, not on the business. If underlying earnings are not actually inflecting, the flattering 13x trailing multiple some screens show is a mirage and the real figure is closer to 23x, a full price for 1% revenue growth.

Closing thoughts

Nothing in the next two quarters settles this one; there is no single beer count or currency move that resolves the bet, and what actually matters is that the cash keeps compounding while the debt keeps falling. The left tail is a slow one, volumes eroding faster than pricing can patch, and it is worth watching precisely because it arrives quietly rather than in a crash. The fatter tail, on the evidence, is the upside: a durable cash machine deleveraging into a rising buyback at a 9.8% cash yield, where the risk is dead money for a year, not permanent loss. Judgment, not arithmetic: the downside is time, the upside is a re-rating nobody is underwriting.

The bet, restated, is that the world keeps drinking Budweiser, Corona and Stella, that AB InBev keeps nudging the price up on flat volumes, and that the debt keeps shrinking until the buyback does the compounding. It breaks if cases sold fall faster than price can hold, and the one pair of numbers that tells you first is organic volume against organic revenue in the next half. If those two diverge the wrong way, the machine described here has stopped.